Employer coverage for GLP-1 weight-loss drugs is declining, with many dropping these benefits by 2027. However, the FDA recently expanded the label for Eli Lilly's Mounjaro to include cardiovascular risk reduction in type 2 diabetes patients, strengthening its case for insurance coverage in diabetes management. This label does not affect obesity drug coverage but supports Lilly's argument that treating diabetes reduces costly hospital events. Despite price declines, Mounjaro's sales surged 91% in Q2, helping Lilly raise its full-year revenue forecast. The new label may protect diabetes-related reimbursements but is unlikely to reverse cuts in obesity drug coverage.
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting...
